ADMA Biologics Set to Join the S&P SmallCap 600 Index Page 1

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company focused on the manufacturing, marketing and development of specialty biologics, today announced that it will join the S&P SmallCap 600 Index, effective at the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 aims to measure the small-cap segment of the U.S. equity market.

“ADMA’s inclusion in the S&P SmallCap 600 Index is a significant milestone for our company,” said Adam Grossman, President and Chief Executive Officer of ADMA. “We expect this inclusion to increase our visibility within the investment community and the liquidity of our securities as we continue to execute on our top-tier growth strategy.”